25 October 2023
Oxford BioTherapeutics announces partner Boehringer Ingelheim dosed first patient in Phase 2 trial with BI 764532 in small cell lung cancer and other neuroendocrine cancers
BI 764532 was discovered using OBT’s proprietary OGAP® platform, the world's largest, cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targets. Oxford, UK, San Jose, Calif., 24th October 2023 - Oxford BioTherapeutics (OBT), a...
24 October 2023
QV Bioelectronics and Incubate Bio announce successful outcome of strategic collaboration to accelerate new treatment option for Glioblastoma
Manchester, October 24, 2023 – QV Bioelectronics and Incubate Bio announce successful outcome of their strategic collaboration to accelerate the research and development of QV Bioelectronics’ novel modality – GRACE – as a treatment option for Glioblastoma. Dr Chris Bullock, CEO...
11 October 2023
Oxford BioTherapeutics relocates UK Headquarters to strategic and cutting-edge R&D location at The Oxford Science Park
… Oxford, UK and San Jose, Calif., 11 October 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, today announced that it has relocated its UK headquarters to The...
5 October 2023
US FDA Fast Track designation granted to BI 764532 for the treatment of extensive stage small cell lung cancer
… Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers … BI 764532 is an investigational T-cell engager that...
2 October 2023
Pencil Biosciences completes fundraise to develop novel gene editing and modulation technology
2nd October 2023 - Pencil Biosciences is developing a novel gene modulation technology based on a next generation platform and aims to transform the gene editing landscape as applied to therapeutics and industrial biotechnology. The company, based in Alderley Park , Cheshire...
25 September 2023
Report shows YOURmeds medication management system helped councils generate significant cost savings
A Real-World Validation Report from the University of Chester has been published, which evidences the “significant” patient benefits and cost savings Stoke-on-Trent City Council and Manchester City Council generated when using a smart medication management system. The YOURmeds...
14 September 2023
Maxwellia launches new brand of emergency contraception
In their latest move to help widen access to medicines, Maxwellia is delighted to announce the launch of LoviOne®; a new brand of levonorgestrel-based emergency contraception. Set to hit pharmacy shelves this autumn, LoviOne® aims to improve access to emergency contraception...
4 September 2023
Gendius receives UKCA mark for CKD Screen Prioritizer
British health data start-up Gendius has received a UKCA mark for its digital pre-screening technology, the CKD Screening Prioritizer (CSP). The CSP, which is now a registered medical device in the UK, uses readily available data to predict whether a patient is likely to be...
22 August 2023
Infex receives approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces it has received approval to commence dosing the final Phase Ia cohort of healthy volunteers and to proceed to dosing the first cohort in the first-in-patient Phase IIa dose-ranging...
16 August 2023
Infex Therapeutics - Clinical candidate nominated for COV-X programme
COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral candidate … • COV-X outperforms Pfizer’s approved antiviral in a pre-clinical mouse SARS-CoV-2 efficacy trial … • Unlike many competitors, COV-X blocks a unique key protein and has potential for broad...